(Reuters) -Aurinia Pharmaceuticals will stop research and development on its immunotherapies to focus on its kidney disease drug Lupkynis after failing to attract a formal buyout offer, the company said on Thursday.
The Canada-based drugmaker said it had failed to attract a formal offer after it had embarked on a strategic review it launched at the end of June, confirming a Reuters report from earlier in the day.
Aurinia anticipates reducing employee headcount by at least 25% by the end of the first quarter of 2024.
The company also initiated a share repurchase program of up to $150 million.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta and Sriraj Kalluvila)
Comments